TICKERNERD
Menu
ASMBASMBHealthcare · Biotechnology

ASMB Stock Forecast: Assembly Biosciences, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$20
−3.50% on the day

The 5 Wall Street analysts covering Assembly Biosciences, Inc. hold a median 12-month price target of $52 — +158.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 78 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$409.9M
Ticker Nerd rank
78/ 100
Median analyst target
$52
Analysts covering
5
Revenue$13.4M+38.9% y/y
Operating income−$6.3M
Net income−$3.9M
Free cash flow−$15.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.5%
1M
−14.3%
YTD
−40.8%
1Y
−33.2%
From 52W high
−47.7%
From 52W low
+2.3%
$20
$39
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ASMB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Assembly Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
78/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Quality
90
Value
86
Volatility
85
Revisions
69
Size
55
Momentum
54
Issuance
31
Accruals
11

Growth (93): Sales and profits are climbing, and climbing faster than before.

Accruals (11): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ASMB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ASMB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26ASMBHigh $62Median $52Low $43

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $43Median $52High $62

The green dot is the last close — the median target sits +158.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Sept 2026MizuhoMaintainsOutperform$53 → $45
1 Sept 2026UBSInitiatesBuy$52
18 Aug 2026HC Wainwright & Co.ReiteratesBuy$50
18 Aug 2026HC Wainwright & Co.ReiteratesBuy—
15 June 2026MizuhoMaintainsOutperform—
15 June 2026MizuhoMaintainsOutperform$40 → $45
28 May 2026GuggenheimReiteratesBuy—
4 May 2026HC Wainwright & Co.ReiteratesBuy—
6 Apr 2026GuggenheimMaintainsBuy—
26 Mar 2026HC Wainwright & Co.ReiteratesBuy—
22 Dec 2025HC Wainwright & Co.ReiteratesBuy—
20 Nov 2025MizuhoMaintainsOutperform—
14 Oct 2025HC Wainwright & Co.ReiteratesBuy—
24 Sept 2025JMP SecuritiesInitiatesMarket Outperform—
8 Sept 2025GuggenheimMaintainsBuy—
18 Aug 2025HC Wainwright & Co.AssumesBuy$50
25 Mar 2025GuggenheimInitiatesBuy—
24 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
27 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
24 Sept 2024HC Wainwright & Co.ReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ASMB appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ASMB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Assembly Biosciences, Inc. returned −33.2% against +12.4% for the S&P 500, dividends included.

ASMB vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120130Jan 26Apr 26Jul 26Oct 26ASMBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ASMB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−184.1%
Analysts raising
2
Analysts cutting
0
Fundamentals

Assembly Biosciences, Inc. (ASMB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.4×

Cheaper than 38% of US stocks

Price / sales
5.5×

Cheaper than 21% of US stocks

Price / book
1.3×

Cheaper than 60% of US stocks

EV / EBITDA
−10.6×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
38.9%

Higher than 82% of US stocks

Earnings growth (YoY)
38.9%

Higher than 71% of US stocks

Gross margin
—
Operating margin
−47.4%

Higher than 17% of US stocks

Net margin
−0.1%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−0.0%

Higher than 44% of US stocks

Return on assets
−2.7%

Higher than 36% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Assembly Biosciences, Inc. (ASMB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Assembly Biosciences, Inc. has a market value of $409.9M and an enterprise value of $91.8M.

  • Revenue in the twelve months to 30 June 2026: $74.8M. The latest quarter grew 38.9% year on year.

  • Net income over the same four quarters: −$42K, a −0.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$38.6M.

  • Shares outstanding: 19.9M.

  • Trailing P/E: 19.4×; forward P/E: −7.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Assembly Biosciences, Inc. employs 73 people — $1.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

ASMB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ASMBAssembly Biosciences, Inc.$409.9M78
ALTAltimmune, Inc.$396.5M29
ALLOAllogene Therapeutics, Inc.$390.9M74
PROKProKidney Corp.$390.8M38
EDITEditas Medicine, Inc.$409.7M76
CCCCC4 Therapeutics, Inc.$414.6M69
ZURAZura Bio Ltd.$383.3M31

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Assembly Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ASMB news & analysis

Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus

GlobeNewsWire · 29 Oct 2026positive

Assembly Biosciences dosed the first two participants in a Phase 2 study of oral NTCP inhibitor ABI-6250 for chronic hepatitis delta virus. The study will assess safety, pharmacokinetics and antiviral activity, with initial data expected in the fourth quarter of 2027.

Why it matters — The dosing marks the start of Phase 2 evaluation of ABI-6250, and the study will provide data on its safety and antiviral activity in chronic HDV infection.

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

GlobeNewsWire · 5 Oct 2026positive

Assembly Biosciences announced it will present positive Phase 1a safety, tolerability and target engagement data for ABI-6250 at The Liver Meeting 2026. The candidate's pharmacodynamic analysis was recognized as a Poster of Distinction.

Why it matters — This highlights promising early clinical data for a key pipeline candidate, which ASMB watchers would see as encouraging progress for the company.

Best Momentum Stocks to Buy for September 17th

Zacks Investment Research · 17 Sept 2026positive

On September 17th, 2026, Assembly Biosciences (ASMB) was included alongside MSGM and MTG on Zacks Investment Research's Rank #1 (Strong Buy) momentum stocks list.

Why it matters — This listing reflects a top momentum ranking from Zacks, which is a notable positive signal for those following Assembly Biosciences.

New Strong Buy Stocks for September 17th

Zacks Investment Research · 17 Sept 2026positive

Zacks Investment Research added Assembly Biosciences, Inc. (ASMB) to its Zacks Rank #1 (Strong Buy) List on September 17th, 2026, alongside MOV, MAX, MTG, and MSGM. The announcement highlights the stock's inclusion in the research firm's top-rated category.

Why it matters — An ASMB watcher would care because the stock received a Strong Buy ranking from a major research firm, which may draw increased attention from investors.

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

GlobeNewsWire · 10 Sept 2026neutral

Assembly Biosciences announced that its senior management will present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026. The company develops therapeutics targeting serious viral and liver diseases.

Why it matters — The presentation gives ASMB watchers an opportunity to hear directly from senior management about the company at a major investment conference.

FAQ

Frequently asked questions about ASMB stock

What is the ASMB stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Assembly Biosciences, Inc. have a median 12-month price target of $52, with estimates ranging from $43 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ASMB stock a buy right now?

Of the 5 analysts covering Assembly Biosciences, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Assembly Biosciences, Inc. 78 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ASMB?

As at 31 Oct 2026, Assembly Biosciences, Inc. ranks 78 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

Will ASMB stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +158.3% from the last close, and Ticker Nerd's factor model ranks Assembly Biosciences, Inc. 78 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ASMB stock forecast for 2030?

No analyst covering Assembly Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ASMB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $43 to $62 over the next 12 months.

How has ASMB stock performed over the past year?

Assembly Biosciences, Inc. returned -33.2% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Assembly Biosciences, Inc. do?

Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases.

What is the latest news on ASMB?

The most recent item we track (GlobeNewsWire, 29 Oct 2026): "Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus". Assembly Biosciences dosed the first two participants in a Phase 2 study of oral NTCP inhibitor ABI-6250 for chronic hepatitis delta virus. The study will assess safety, pharmacokinetics and antiviral activity, with initial data expected in the fourth quarter of 2027.

Company

About Assembly Biosciences, Inc.

Assembly Biosciences Inc. is a clinical-stage biotechnology company focused on developing small-molecule therapeutics for serious viral and liver diseases. Its current pipeline includes investigational treatments for recurrent genital herpes, hepatitis B virus, hepatitis D virus, and other infectious conditions, with programs designed to target key stages of viral replication and disease progression. The company also advances research in related areas such as cholestatic liver disease and microbiome-linked disorders through orally delivered therapeutic candidates. Assembly Biosciences Inc. works across discovery, preclinical, and clinical development, positioning itself within the infectious disease and liver disease segments of the biotechnology market. Headquartered in South San Francisco, California, the company concentrates on creating novel treatment approaches intended to address unmet medical needs in virology and liver health.

CEO Mr. Jason A. Okazaki J.D. · 73 employees · United States · https://www.assemblybio.com